Marked increase in proton pump inhibitors use in Australia

Hollingworth, Samantha, Duncan, Emma L. and Martin, Jennifer H (2010) Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiology and Drug Safety, 19 10: 1019-1024. doi:10.1002/pds.1969


Author Hollingworth, Samantha
Duncan, Emma L.
Martin, Jennifer H
Title Marked increase in proton pump inhibitors use in Australia
Journal name Pharmacoepidemiology and Drug Safety   Check publisher's open access policy
ISSN 1099-1557
1053-8569
Publication date 2010-10-01
Sub-type Article (original research)
DOI 10.1002/pds.1969
Volume 19
Issue 10
Start page 1019
End page 1024
Total pages 6
Place of publication West Sussex, United Kingdom
Publisher John Wiley & Sons
Collection year 2011
Language eng
Subject 1103 Clinical Sciences
1115 Pharmacology and Pharmaceutical Sciences
Formatted abstract
Objectives: To examine the trends in the prescribing of subsidised proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs), in the Australian population from 1995 to 2006 to encourage discussion regarding appropriate clinical use. PPIs and H2RAs are the second highest drug cost to the publicly subsidised Pharmaceutical Benefits Scheme (PBS).
Design: Government data on numbers of subsidised scripts, quantity and doses for PPIs and H2RAs were analysed by gender and age, dose and indication.
Main outcome measure: Drug utilisation as DDD [defined daily dose]/1000 population/day.
Results:
The use of combined PPIs increased by 1318%. Utilisation increased substantially after the relaxation of the subsidised indications for PPIs in 2001. Omeprazole had the largest market share but was substituted by its S-enantiomer esomeprazole after its introduction in 2002. There was considerable use in the elderly with the peak use being in those aged 80 years and over. The utilisation of H2RAs declined 72% over 12 years.
Conclusions: PPI use has increased substantially, not only due to substitution of H2RAs but to expansion in the overall market. Utilisation does not appear to be commensurate with prevalence of gastro-oesophageal reflux disease (GORD) nor with prescribing guidelines for PPIs, with significant financial costs to patients and PBS. This study encourages clinical discussion regarding quality use of these medicines. © 2010 John Wiley & Sons, Ltd.
Keyword Proton pump inhibitors
Gastro-oesophageal reflux disease
Prescribing
Utilisation
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Public Health Publications
School of Medicine Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 39 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 12 Oct 2010, 00:47:36 EST by Ms May Balasaize on behalf of School of Public Health